کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
10968162 | 1102872 | 2013 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
An overview of meningococcal disease in India: Knowledge gaps and potential solutions
ترجمه فارسی عنوان
یک مرور کلی از بیماری مننگوکوک در هند: شکاف های دانش و راه حل های بالقوه
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
GMIPBMNCDCRT-PCRIAPEpidemiology - اپیدمیولوژی(همهگیرشناسی)Meningococcal disease - بیماری مننگوکوکNongovernmental organizations - سازمان های غیر دولتیNGOs - سازمان های غیر دولتیCSF - مایع مغزی نخاعیCerebrospinal fluid - مایع مغزی نخاعیNeisseria meningitidis - نایسریا مننژیتیس، مننگوکوکHaemophilus influenzae type b - نوع hemophilus influenzae bIndia - هندوستانHib - هیبVaccines - واکسنpolymerase chain reaction - واکنش زنجیره ای پلیمرازreal-time polymerase chain reaction - واکنش زنجیره ای پلیمراز واقعی در زمان واقعیPCR - واکنش زنجیرهٔ پلیمراز
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
ایمونولوژی
چکیده انگلیسی
The Global Meningococcal Initiative (GMI) consists of an international group of scientists and clinicians, with expertise in meningococcal immunology, epidemiology, public health and vaccinology that aims to prevent meningococcal disease worldwide through education, research, cooperation and vaccination. In India, there is no national policy on routine meningococcal vaccination to control the disease. The GMI convened a meeting in India, with local medical leaders and public policy personnel, to gain insight into meningococcal disease burden and current surveillance and vaccination practices in the country. Neisseria meningitidis is the third most common cause of sporadic bacterial meningitis in children <5 years, with higher incidence in temperate northern versus tropical southern India. Incidence is not reliably known due to suboptimal surveillance and insufficient microbiological support for diagnosis. Since 2005, there have been a number of outbreaks, all attributable to serogroup A. Outbreak responses were ad hoc and included mandatory case reporting by hospitals in Delhi, temporary strengthening of laboratory diagnostics, chemoprophylaxis of close contacts/high-risk groups and limited reactive use of polysaccharide vaccine. Although a conjugate serogroup A vaccine (MenAfriVacâ¢) is manufactured in India, it is not presently used in India. Epidemiological data on meningococcal disease in India are sparse. Meningococcal disease control efforts should focus on establishing systematic surveillance and educating physicians and officers of the Immunization Division of the Ministry of Health on the importance of N. meningitidis as a cause of morbidity and mortality. Conjugate vaccine should be used for outbreak control and the immunization of high-risk persons.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Vaccine - Volume 31, Issue 25, 7 June 2013, Pages 2731-2737
Journal: Vaccine - Volume 31, Issue 25, 7 June 2013, Pages 2731-2737
نویسندگان
T. Jacob John, Sunil Gupta, A.J. Chitkara, Ashok Kumar Dutta, Ray Borrow,